Progression-free survival stratified by level of measurable residual disease at the start of maintenance therapy (A) and after 12 months of maintenance therapy (B) in patients with a very good partial response or better. From Supplemental Figure 1 in Perrot et al., Blood. 2018;132:2456-2464.